Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from NGM Biopharmaceuticals Inc (NGM) is now available.
NGM Biopharmaceuticals, Inc. has successfully concluded a merger with Atlas Neon Parent, Inc., culminating in the acquisition of a majority stake in NGM Bio by Atlas Neon’s subsidiary through a tender offer at $1.55 per share. The transaction involved terminating a previous Sale Agreement with Jefferies LLC, rolling over significant shares from key stockholders, and amending the company’s certificate of incorporation and bylaws. Consequently, NGM Bio’s common stock will be delisted from Nasdaq, and the company will cease its reporting obligations under the Exchange Act, marking a new chapter in its corporate life.
For an in-depth examination of NGM stock, go to TipRanks’ Stock Analysis page.